TY - JOUR
T1 - Predictive and prognostic value of human copper transporter 1 (hCtr1) in patients with stage III non-small-cell lung cancer receiving first-line platinum-based doublet chemotherapy
AU - Chen, Helen H.W.
AU - Yan, Jiang Jou
AU - Chen, Wen Chung
AU - Kuo, Macus Tien
AU - Lai, Yu Hsuan
AU - Lai, Wu Wei
AU - Liu, Hsiao Sheng
AU - Su, Wu Chou
N1 - Funding Information:
This work was supported by National Cheng Kung University Hospital, Tainan, Taiwan [grant number 9904005 ]; National Science Council, Taiwan [grant number 97-2314-B-006-043 and 99-2314-B-006-038-MY3]; and Department of Health, Taiwan [grant numbers 99-TD-B-111-002 and 99-TD-B-111-003 ]. The authors would like to thank the Cancer Registry at the Cancer Center of National Cheng Kung University Hospital, Tainan, Taiwan for providing data.
PY - 2012/2
Y1 - 2012/2
N2 - Background: Recent studies have shown that human copper transporter 1 (hCtr1), the major copper influx transporter, is involved in the transport of platinum-based antitumor agents. We investigated the predictive and prognostic values of hCtr1, and copper efflux transporters ATP7A and ATP7B, in patients with locally advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-based chemotherapy. Methods: From 2004 to 2009, we identified 54 consecutive stage III NSCLC patients who underwent first-line platinum-based doublet chemotherapy. Immunohistochemical studies of hCtr1, ATP7A and ATP7B on the paraffin-embedded pre-treatment tumor samples were performed and correlated with chemotherapy response and survival. Results: Overexpression of hCtr1, ATP7A and ATP7B were observed in 68%, 48% and 74% of the participants, respectively. hCtr1 overexpression was associated with better chemotherapy responses (P< 0.01); whereas ATP7A and ATP7B were not. Patients with hCtr1 overexpressing tumors had better progression-free survival (PFS) and overall survival (OS) (P= 0.01 and 0.047, respectively). In multivariate analyses for chemotherapy response and PFS, only hCtr1 overexpression emerged as a favorable independent predictive and prognostic factor (all P< 0.01). Conclusion: This is the first report to state that hCtr1 is not only an independent predictor of platinum-based chemotherapy response but also a prognostic factor in stage III NSCLC.
AB - Background: Recent studies have shown that human copper transporter 1 (hCtr1), the major copper influx transporter, is involved in the transport of platinum-based antitumor agents. We investigated the predictive and prognostic values of hCtr1, and copper efflux transporters ATP7A and ATP7B, in patients with locally advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-based chemotherapy. Methods: From 2004 to 2009, we identified 54 consecutive stage III NSCLC patients who underwent first-line platinum-based doublet chemotherapy. Immunohistochemical studies of hCtr1, ATP7A and ATP7B on the paraffin-embedded pre-treatment tumor samples were performed and correlated with chemotherapy response and survival. Results: Overexpression of hCtr1, ATP7A and ATP7B were observed in 68%, 48% and 74% of the participants, respectively. hCtr1 overexpression was associated with better chemotherapy responses (P< 0.01); whereas ATP7A and ATP7B were not. Patients with hCtr1 overexpressing tumors had better progression-free survival (PFS) and overall survival (OS) (P= 0.01 and 0.047, respectively). In multivariate analyses for chemotherapy response and PFS, only hCtr1 overexpression emerged as a favorable independent predictive and prognostic factor (all P< 0.01). Conclusion: This is the first report to state that hCtr1 is not only an independent predictor of platinum-based chemotherapy response but also a prognostic factor in stage III NSCLC.
UR - http://www.scopus.com/inward/record.url?scp=84855418559&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84855418559&partnerID=8YFLogxK
U2 - 10.1016/j.lungcan.2011.06.011
DO - 10.1016/j.lungcan.2011.06.011
M3 - Article
C2 - 21788094
AN - SCOPUS:84855418559
SN - 0169-5002
VL - 75
SP - 228
EP - 234
JO - Lung Cancer
JF - Lung Cancer
IS - 2
ER -